Company intelligence / Profile preview
Genmab
Copenhagen, Denmarkgenmab.com ↗
- Ownership
- Public · GMAB
- Employees
- ~2204
- Development stage
- Other
01
Overview
Genmab has several approved products including Darzalex (daratumumab) for multiple myeloma and AL amyloidosis, Kesimpta (ofatumumab) for relapsing multiple sclerosis, Tepezza (teprotumumab) for thyroid eye disease, Tivdak (tisotumab vedotin) for cervical cancer, and EPKINLY (epcoritamab) for follicular lymphoma[3][4].
- Therapeutic areas
- OncologyEndocrinologyNeurologyHematology
- Modalities
- Antibody therapeuticsmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
40 assets39 more assets in the full pipeline.
03
Partnerships
Revitope Oncology Inc.pharmaceutical and biotechnology companies for co-development and commercialization
04
Financials
- Market cap
- $32.4B
- Total revenue
- $3.7B
- Enterprise value
- $36.2B
Beyond the preview
Go deeper on Genmab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genmab.